Sun Pharmaceutical Industries is trading higher by 3.5% at Rs 600, after falling nearly 7% in past four trading sessions on the Bombay Stock Exchange (BSE). The stock is largest gainer among benchmark index S&P BSE Sensex at 1020 hours.
Till yesterday, shares of drug maker has fallen 6.75% to Rs 580 from Rs 622 on March 5, on reports that the company has recalled 2,528 bottles of its generic version of diabetes drug Glumetza. The benchmark index has gained 2.6% during the same period.
According to FDA statement, Sun began recalling the bottles of metformin HCL extended-release tables on January 28, 2014, after it received a customer complaint that one of the bottles contained tablets of epilepsy drug Gabapentin.
The stock opened at Rs 583 and has seen a combined around 938,000 shares changed hands on the counter so far on the BSE and NSE.
Till yesterday, shares of drug maker has fallen 6.75% to Rs 580 from Rs 622 on March 5, on reports that the company has recalled 2,528 bottles of its generic version of diabetes drug Glumetza. The benchmark index has gained 2.6% during the same period.
According to FDA statement, Sun began recalling the bottles of metformin HCL extended-release tables on January 28, 2014, after it received a customer complaint that one of the bottles contained tablets of epilepsy drug Gabapentin.
The stock opened at Rs 583 and has seen a combined around 938,000 shares changed hands on the counter so far on the BSE and NSE.
